Pyridazine compounds for inhibiting NLRP3

A compound of Formula (II):

• or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof;
• wherein:
• Y is phenyl independently substituted with one, two, or three substituents selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, halo, cyano, and —R4OR5, wherein at least one substitution is substituted at the para-position of the phenyl ring;
• R1 is C1-C6 alkyl independently substituted with one or more halo and —R4OR5;
• R2 and R3, together with the atoms to which they are attached, form a 5- to 9-membered heteroaryl optionally substituted with one or more R2a;
• R2a is hydrogen, C1-C6 alkyl, halo or C1-C6 haloalkyl;
• R4 is absent, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• and
• R5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C5-C10 aryl, or 5- to 9-membered heteroaryl.